Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) April 26, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous Polyposis (FAP)...

7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding HOUSTON, May 22, 2023 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”) announced today that it has been awarded $13.5MM in nondilutive grant funds from the Cancer Prevention &...

Invectys, Inc. Appoints François Lescure as General Manager of its R&D Subsidiary, Invectys, SAS  Houston, Texas, USA, April 11, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. of Houston, Texas, a clinical stage immunotherapy company which is developing a next generation of therapies to meet the needs...

INVECTYS INC. TO PARTICIPATE IN THE 2021 ROTH VIRTUAL HEALTHCARE PRIVATE COMPANY FORUM ON JUNE 28TH, 2021 Houston, Texas, USA, June 25, 2021 (GLOBE NEWSWIRE) -- Invectys Inc. a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products...

Invectys nominates Rosemary Williams, CPA, as Vice-President for Administration and Controller Houston, TX, USA, June 01, 2021 (GLOBE NEWSWIRE) -- Invectys Inc. of Houston, Texas, a clinical stage immunotherapy company dedicated to the development of a next generation of therapies to meet the...